Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial.

Assaf P Oron; Roy Burstein; Laina D Mercer; Ahmed M Arzika; Khumbo Kalua; Zakayo Mrango; Sheila K West; Robin L Bailey ORCID logo; Travis C Porco; Thomas M Lietman; (2020) Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial. The American journal of tropical medicine and hygiene, 103 (3). pp. 1295-1300. ISSN 0002-9637 DOI: 10.4269/ajtmh.18-1004
Copy

We examined whether baseline mortality risk, as a function of child age and site, modified the azithromycin mortality-reduction effect in the Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) clinical trial. We used the Cox proportional hazards model with an interaction term. Three models were examined representing three sources for the baseline-risk covariate: two using sources external to MORDOR and the third leveraging data within MORDOR. All three models provided moderate evidence for the effect becoming stronger with increasing baseline mortality (P = 0.02, 0.02, and 0.07, respectively) at the rate of approximately 6-12% additional mortality reduction per doubling of baseline mortality. Etiological and programmatic implications of these findings are discussed.


picture_as_pdf
Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial.pdf
subject
Published Version
Available under Creative Commons: 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads